Valiant Laboratories
69.79
-3.20(-4.38%)
Market Cap₹379.05 Cr
PE Ratio83.01
IndustryHealthcare
Company Performance:
1D-4.38%
1M-19.65%
6M-30.25%
1Y-33.41%
5Y-55.86%
View Company Insightsright
More news about Valiant Laboratories
25Sept 25
Valiant Laboratories Announces Key Management Changes and Auditor Appointment at AGM
Valiant Laboratories held its 4th AGM on September 25, 2025, approving key management changes and a new auditor appointment. Mr. Santosh Vora was reappointed as Managing Director, while Mr. Paresh Shah's role changed to Whole-Time Director & CFO. M/s. Mehta & Mehta were appointed as Secretarial Auditors for five years. The company acknowledged challenges in the paracetamol API segment but outlined strategic responses including capacity expansion, supply chain strengthening, and diversification into specialty chemicals. Management expressed confidence in future growth despite current market pressures.
08Aug 25
Valiant Laboratories Reports Robust Q1 Results, Approves Key Management Changes
Valiant Laboratories reported a significant increase in Q1 financial performance, with revenue from operations growing 147.9% year-over-year to Rs. 4,682.27 crore. The company turned profitable with a net profit of Rs. 182.09 crore, compared to a loss in the previous year. The board approved the redesignation of Mr. Paresh Shah as Whole-time Director and Key Managerial Personnel for a five-year term. Additionally, M/s. Mehta & Mehta was appointed as the new Secretarial Auditor for a five-year term. Both appointments are subject to shareholder approval at the upcoming Annual General Meeting.
15Jul 25
Valiant Laboratories Announces Rights Issue: ₹75 Per Share with 1:4 Entitlement Ratio
Valiant Laboratories Limited has approved a rights issue of up to 1,08,62,500 equity shares at ₹75 per share, with an entitlement ratio of 1:4. The issue will open on July 28, 2025, and close on August 8, 2025, with a record date of July 19, 2025. The total issue size is valued at ₹814.69 crore. The company has received in-principle approvals from NSE and BSE for the rights issue.
20May 25
Valiant Laboratories Reports Turnaround in Q4 with Improved EBITDA and Revenue
Valiant Laboratories announced improved Q4 results, reversing previous losses. EBITDA reached ₹38.30 crore, up from a ₹45.30 crore loss last year. Revenue nearly doubled to ₹577.90 crore from ₹305.90 crore. The company reported a net profit of ₹7.04 crore, compared to a ₹12.40 crore loss in the same quarter last year.
Valiant Laboratories
69.79
-3.20
(-4.38%)
1 Year Returns:-33.41%
Industry Peers
Sun Pharmaceutical
1,780.80
(+0.06%)
Divis Laboratories
6,359.00
(-0.22%)
Torrent Pharmaceuticals
3,718.40
(+0.87%)
Cipla
1,504.00
(-0.52%)
Dr Reddys Laboratories
1,226.20
(-1.42%)
Zydus Life Science
926.65
(+0.25%)
Mankind Pharma
2,222.70
(-0.87%)
Lupin
1,999.60
(-1.47%)
Aurobindo Pharma
1,194.00
(-0.99%)
Alkem Laboratories
5,625.00
(-1.32%)